Parkinson's Disease Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The Parkinson’s disease market was valued at USD 3.68 Billion in 2025. It is poised to grow at a CAGR of 5.10% during the forecast period of 2026-2035, and reach USD 6.05 Billion by 2035. The market growth is driven by increasing Parkinson’s awareness, technological innovations in deep brain stimulation, rising healthcare expenditure, supportive government initiatives, and expansion of diagnostic and treatment services improving patient quality of life globally.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the Parkinson’s Disease Market

United States: The Parkinson’s Disease Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. 31 force majeure declarations by polymer suppliers, polypropylene and polyethylene price spikes, and chemical manufacturer surcharges of up to 30% are flowing through supply chains. U.S. consumer inflation is projected at 4.2% for 2026, above pre-war forecasts, with fuel costs above USD 4 per gallon compressing household discretionary budgets. Retail supply chains are absorbing the combined impact of 30% higher freight costs, 15-20% packaging material inflation, and rising transport fuel costs, compressing retailer margins. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets.

Iran: Iran's domestic Parkinson’s Disease sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.

Israel: Israel's Parkinson’s Disease sector is experiencing near-term disruption from wartime conditions. Consumer spending on non-essential categories has declined as millions of Israelis regularly shelter from missile and drone alerts. Supply chain logistics are disrupted by regional airspace closures, elevated war-risk insurance premiums, and the suspension of major carrier services through the region. International business partnerships with Israeli companies have been temporarily suspended. Post-conflict reconstruction and recovery demand is expected to provide meaningful demand acceleration across affected market segments once operational conditions normalise.

Key Takeaways

Government

• Relevant consumer protection agencies should monitor retail pricing for evidence of disproportionate margin-taking on top of genuine supply cost increases, ensuring that conflict-related cost inflation is not being amplified by opportunistic pricing behaviour.
• Governments should consider targeted consumer support measures for lower-income households most exposed to rising fuel and food costs, preventing conflict-driven inflation from creating acute hardship among economically vulnerable populations.
• Trade authorities should work with the parkinson’s disease industry to identify import diversification opportunities that reduce dependence on Gulf-disrupted supply chains, stabilising product availability and moderating consumer price inflation.

Market

• U.S. consumer inflation projected at 4.2% for 2026, gasoline above USD 4 per gallon, and global food price increases from fertilizer and logistics inflation are creating the most challenging consumer spending environment since 2022.
• Premium and essential categories within the parkinson’s disease market show different demand trajectories: premium segments serving ultra-high-net-worth consumers remain resilient, while mass-market discretionary segments face meaningful softening.
• Supply chain cost increases from 30% higher freight, 15-20% packaging inflation, and rising input material costs are compressing retailer and brand margins, creating pressure for pricing adjustments that may further moderate volume demand.

Procurement

• Consumer goods procurement teams should review packaging material sourcing, building 60-90 day buffer inventory of petroleum-derived packaging materials before further feedstock cost increases from the Gulf supply shock are transmitted into manufacturing costs.
• Logistics procurement managers should lock in freight contracts at current rates before further diesel cost increases are passed through by carriers, and evaluate route optimisation strategies that reduce fuel cost exposure.
• Retail and brand buyers should update 2026 cost models to incorporate 30% higher freight costs, 15-20% packaging material inflation, and rising input material prices, ensuring that margin targets and pricing strategies reflect the new cost environment.

Key Market Trends and Insights

• By drug class, carbidopa-levodopa commanded over 35% of the market share in the historical period.
• By route of administration, oral formulations held about 75% share of the market size in the historical period.
• By region, the United States led with approximately 41% share of the market in the historical period.

Market Size and Forecast

• Market Size (2025): USD 3.68 Billion
• Projected Market Size (2035): USD 6.05 Billion
• CAGR (2026-2035): 5.10%

Parkinson’s Disease Market Overview

The market is witnessing steady growth due to rising prevalence, an aging population, and increased awareness of neurological disorders. Advances in Parkinson's disease-modifying therapy and supportive care options are driving treatment adoption. Strong healthcare infrastructure, early diagnosis initiatives, and growing investment in research and development further enhance market expansion, improving patient outcomes and quality of life worldwide. The market reached a value of approximately USD 3.68 Billion in 2025.

Parkinson’s Disease Market Growth Drivers

Novel Dopamine Agonist NDA Submission Propelling Parkinson's Disease Market Expansion

Growing neurological disease burden and increasing investment in first-in-class oral therapies are strengthening the Parkinson's disease market. Rising unmet need is accelerating clinical innovation. For instance, in October 2025, AbbVie submitted an NDA to the FDA for tavapadon, a selective D1/D5 receptor dopamine agonist and one of the first novel Parkinson's drug candidate in 50 years, expected to expand the addressable patient population.

Parkinson’s Disease Market Trends

Key trends shaping the market include rising adoption of deep brain stimulation, increasing awareness, technological innovations, and the expansion of therapeutic and diagnostic services globally.

Rising Strategic Investment in Parkinson's Disease-Modifying Therapy Fuels Market Growth

Rising disease prevalence and growing R&D investment are redefining the Parkinson's disease landscape. Expanding strategic collaborations are enabling novel neurodegeneration approaches. For instance, in September 2025, Novartis signed a licensing deal with Arrowhead Pharmaceuticals for ARO-SNCA, an RNAi-based Parkinson's disease-modifying therapy, valued at USD 2.2 billion, projected to accelerate pipeline development and expand neuroprotective treatment options through the forecast period.

Parkinson’s Disease Market Segmentation

Market Breakup by Drug Class

• MAO-B Inhibitors
• Carbidopa/levodopa
• COMT Inhibitors
• Dopamine Agonists
• Anticholinergics
• Amantadine
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Channel

Market Breakup by End User

• Hospital
• Specialty Clinics
• Homecare Settings
• Academic and Healthcare Settings
• Others

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Parkinson’s Disease Market Share

Oral Route of Administration Likely to Lead the Market Segment

Oral route of administration dominated the market in the historical period, accounting for about 75% of the total market. Their widespread adoption is driven by patient convenience, ease of dosing, and adherence to therapy. Among treatments, levodopa remains the most prescribed therapy, supporting consistent demand and reinforcing the preference for oral administration across global Parkinson’s care settings.

Parkinson’s Disease Market Analysis by Country

The United States is expected to lead the market, capturing approximately 41% of the total market. This dominance is supported by advanced healthcare infrastructure, early diagnosis initiatives, and high treatment adoption rates. Specifically, dopamine agonist therapies are increasingly utilized to manage motor symptoms, driving both clinical adoption and market growth in the region.

Leading Players in the Parkinson’s Disease Market

The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Pfizer, Inc.

Founded in 1849 and headquartered in New York, USA, Pfizer, Inc. develops therapies for neurological disorders, including Parkinson’s Disease. The company’s portfolio features dopamine agonist medications that help manage motor symptoms. Pfizer continues research on disease-modifying therapies and adjunctive treatments to improve patient quality of life and reduce motor complications.

Medtronic plc

Established in 1949, Medtronic plc is headquartered in Dublin, Ireland. In Parkinson’s Disease, it is recognized for deep brain stimulation systems that provide precise neuromodulation for motor symptom control. Medtronic also supports programmable implantable devices and patient monitoring platforms, aiming to enhance therapeutic outcomes and advance Parkinson’s disease-modifying research.

GlaxoSmithKline plc.

Headquartered in London, UK, and founded in 2000 through a merger, GlaxoSmithKline plc. offers a range of Parkinson’s Disease therapies. Their portfolio includes MAO-B inhibitors that support symptom management and adjunctive care. GSK emphasizes research on innovative compounds targeting disease progression, as well as improving patient adherence and long-term treatment outcomes.

AbbVie Inc.

AbbVie Inc., founded in 2013 and based in North Chicago, USA, develops therapies addressing neurodegenerative conditions. In Parkinson’s Disease, AbbVie focuses on COMT inhibitors and dyskinesia management solutions. The company actively invests in clinical trials for novel disease-modifying therapies while providing supportive care options to enhance patient motor function and daily living activities.

Other key players in the market are Viatris, Teva Pharmaceutical Industries Ltd, H. Lundbeck A/S, Merck & Co., Inc., Supernus Pharmaceuticals, Inc., and Novartis AG.

Key Questions Answered in the Parkinson’s Disease Market

• What was the Parkinson’s disease market value in 2025?
• What is the Parkinson’s disease market forecast outlook for 2026-2035?
• What major factors aid the demand for Parkinson’s disease market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major Parkinson’s disease market trends?
• Which drug class is expected to dominate the market segment?
• Which route of administration is expected to dominate the market segment?
• Which distribution channel is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the Parkinson’s disease market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?